Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.3K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.3K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.3K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

324
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
324
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.3K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.3K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide identification of CAD and CCoAOMT gene families in soybean and analysis of expression patterns under <i>Peronospora manshurica</i> (<i>P. manshurica</i>) infection.

Frontiers in plant science·2026
Same author

Toxicological Effects of Phthalate Plasticizers in Zebrafish Models: A Review.

Molecules (Basel, Switzerland)·2026
Same author

The "Hit-and-Run" legacy: epigenetic locking and the survival switch in H. pylori-associated gastric cancer.

Cell death discovery·2026
Same author

Dscam alternative splicing tunes intestinal immunity and microbiota homeostasis in the Chinese mitten crab.

Fish & shellfish immunology·2026
Same author

Lactylation of PTBP1 drives a pro-apoptotic positive feedback loop in microglia following oxygen-glucose deprivation/reoxygenation-induced injury.

Cell death & disease·2026
Same author

Bacterial outer membrane proteins modulate extracellular Dscam isoforms and Dorsal-mediated immunity in Eriocheir sinensis.

Fish & shellfish immunology·2026

Related Experiment Video

Updated: Dec 11, 2025

Biochemical Reconstitution of Steroid Receptor&#x2022;Hsp90 Protein Complexes and Reactivation of Ligand Binding
11:07

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding

Published on: September 21, 2011

16.8K

Characterization of β-Sitosterol for Potential Selective GR Modulation.

Yue Leng1, Yonghai Sun1, Chengyu Lv2

  • 1College of Food Science and Engineering, Jilin University, Changchun 130062, China.

Protein and Peptide Letters
|August 18, 2020
PubMed
Summary

Beta-sitosterol, a plant compound, may act as a selective glucocorticoid receptor (GR) modulator. It inhibits inflammatory gene expression without activating GR-mediated transactivation, suggesting potential therapeutic applications.

Keywords:
Glucocorticoid receptordissociatemolecular docking.transactivationtransrepressionβ-sitosterol

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.3K
Isolation and Purification of Fungal &#946;-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

2.3K

Related Experiment Videos

Last Updated: Dec 11, 2025

Biochemical Reconstitution of Steroid Receptor&#x2022;Hsp90 Protein Complexes and Reactivation of Ligand Binding
11:07

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding

Published on: September 21, 2011

16.8K
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.3K
Isolation and Purification of Fungal &#946;-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

2.3K

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Biochemistry

Background:

  • Glucocorticoids (GCs) are potent anti-inflammatory drugs but cause metabolic side effects.
  • Beta-sitosterol, found in vegetable oil, exhibits anti-inflammatory properties.
  • Selective GR modulators are sought to separate therapeutic effects from side effects.

Purpose of the Study:

  • To investigate if beta-sitosterol acts as a selective GR binder.
  • To evaluate beta-sitosterol's ability to dissociate GR transrepression from transactivation.
  • To explore beta-sitosterol as a potential therapeutic agent for inflammatory conditions.

Main Methods:

  • Molecular docking to predict beta-sitosterol binding to the GR ligand-binding domain.
  • Reporter gene assays to assess GR transcriptional activity.
  • Quantitative PCR to analyze GR target gene modulation.

Main Results:

  • Beta-sitosterol binds to the GR ligand-binding domain but does not induce transactivation.
  • Beta-sitosterol inhibits the expression of GR target transrepressed genes.
  • Beta-sitosterol does not activate GR transactivation-dependent genes.

Conclusions:

  • Beta-sitosterol demonstrates potential as a selective GR modulator.
  • This dissociation of transactivation and transrepression suggests a safer therapeutic profile.
  • Further research into beta-sitosterol's therapeutic applications is warranted.